Welcome to our dedicated page for Traws Pharma news (Ticker: ONTX), a resource for investors and traders seeking the latest updates and insights on Traws Pharma stock.
Traws Pharma Inc (ONTX) is a clinical-stage biopharmaceutical company advancing novel cancer therapies through targeted small molecule drug development. This dedicated news hub provides investors and industry observers with timely updates on the company's scientific progress and corporate developments.
Access official press releases, clinical trial milestones, and financial filings in one centralized location. Our curated collection includes updates on translational research breakthroughs, regulatory submissions, and strategic partnerships relevant to ONTX's oncology pipeline.
Key content categories include clinical program advancements, intellectual property developments, and financial performance reports. All materials are sourced directly from company communications and verified financial disclosures to ensure accuracy.
Bookmark this page for streamlined tracking of Traws Pharma's progress in developing precision therapies that aim to improve cancer treatment outcomes. Check regularly for updates on their proprietary drug discovery platform and pipeline candidates moving through clinical evaluation.
Onconova Therapeutics, Inc. (NASDAQ: ONTX) announced that Steven Fruchtman, M.D., President and CEO, will present a company overview and hold one-on-one meetings during the Spring 2021 Oncology Investor Conference from March 29 to April 2, 2021. Fruchtman’s presentation is scheduled for April 1, 2021, at 11:50 a.m. Eastern time. The event highlights Onconova's ongoing clinical trials, including its Phase 1 trials for multi-kinase inhibitor ON 123300 in the U.S. and China. A webcast will be available on their website starting April 2, 2021.
Onconova Therapeutics, Inc. (NASDAQ: ONTX) announced its financial results for the year ended December 31, 2020, highlighting significant developments in its clinical pipeline. Key milestones include FDA clearance for Phase 1 studies of ON 123300, a multi-kinase inhibitor targeting advanced cancers. The company raised $35.2 million from equity offerings, bringing cash and equivalents to approximately $49.5 million. In 2020, Onconova reported a net loss of $25.2 million, equating to $0.14 per share. The company expects this funding will sustain operations and trials for over 18 months.
Onconova Therapeutics (NASDAQ: ONTX) is set to release its year-end 2020 financial results on March 11, 2021, after market close. A conference call will follow at 4:30 p.m. ET to discuss the results and provide updates on its pipeline. The company is advancing its multi-kinase inhibitor ON 123300 into a Phase 1 trial in the U.S. in 2021, alongside ongoing studies in China. Additionally, oral rigosertib is being investigated for KRAS+ lung adenocarcinoma and preclinical work is ongoing for COVID-19.
Onconova Therapeutics, a biopharmaceutical firm focused on cancer treatments, announced participation in three virtual investment conferences in March 2021. Steven Fruchtman, M.D., will be attending:
- H.C. Wainwright Global Life Sciences Virtual Conference (March 9-10)
- Virtual 33rd Annual Roth Conference (March 15-17)
- Maxim Group Emerging Growth Virtual Conference (March 17-18)
The company also plans to start a Phase 1 trial for its multi-kinase inhibitor, ON 123300, in the U.S. this year, while ongoing studies for oral rigosertib target KRAS+ lung cancer patients.
Onconova Therapeutics (NASDAQ: ONTX) has announced that it has regained compliance with Nasdaq's minimum bid price requirement after its stock closed above $1.00 for ten consecutive business days. This notification allows the company to maintain its listing status. CEO Steven Fruchtman expressed gratitude for investor support and emphasized that 2021 is pivotal for Onconova as they prepare to initiate a Phase 1 trial for their drug candidate ON 123300 in patients with advanced cancer.
Onconova Therapeutics has successfully closed its public offering, selling 28,750,000 shares at $1.00 each, generating $28.75 million in gross proceeds. The offering includes 3,750,000 shares following the underwriters' over-allotment exercise. Guggenheim Securities served as the sole book-running manager for this transaction. The shares were offered under a previously-filed shelf registration statement. Proceeds from the offering may support Onconova's ongoing clinical trials for its cancer treatment candidates, including ON 123300 and rigosertib.
Onconova Therapeutics (NASDAQ: ONTX) has announced that Steven Fruchtman, M.D., President & CEO, will present a virtual company update at the 2021 BIO CEO & Investor Digital Conference from February 16-18, 2021. The presentation will be on-demand starting February 19. The company focuses on developing novel cancer treatments, including the multi-kinase inhibitor ON 123300, currently in Phase 1 trials in China, and rigosertib, which is also under investigation for COVID-19. For more details, visit www.onconova.com.
Onconova Therapeutics announced an underwritten public offering of 25 million shares at $1.00 per share, aiming to raise $25 million in gross proceeds before expenses. Additionally, the underwriters have the option to purchase up to 3.75 million more shares. The offering is expected to close around February 16, 2021. Guggenheim Securities is the sole book-running manager, with Maxim Group and Noble Capital Markets as co-managers. The shares are being offered under a previously filed shelf registration statement.
Onconova Therapeutics (NASDAQ: ONTX) has announced plans for an underwritten public offering of its common stock, expected to be subject to market conditions. The company intends to offer all shares and may grant underwriters a 30-day option to purchase up to 15% more. Proceeds from the offering will be allocated for working capital and corporate purposes, with interim investments planned in short-term, interest-bearing securities. Guggenheim Securities is the lead manager for this offering, with Noble Capital Markets as co-manager.
Onconova Therapeutics (NASDAQ: ONTX) announced that CEO Steven Fruchtman will present a company overview at NobleCon17 on January 20, 2021, at 4:30 PM EST. The virtual conference is free to attend and includes a 20-minute presentation followed by a Q&A session. Onconova focuses on cancer treatments and is currently advancing its multi-kinase inhibitor ON 123300 in Phase 1 trials in China and the U.S. Additionally, rigosertib is in a Phase 1 study for KRAS+ lung adenocarcinoma. A webcast of the presentation will be available on the company's website.
